Robert Fisher | Senior Advisor for CBRN and Pandemic Influenza, Office of Counterterrorism and Emerging Threats (OCET)
Food and Drug Administration (FDA)

Robert Fisher, Senior Advisor for CBRN and Pandemic Influenza, Office of Counterterrorism and Emerging Threats (OCET), Food and Drug Administration (FDA)

Robert W. Fisher, Ph.D. sits in FDA’s Office of Counterterrorism and Emerging Threats (OCET) as the Senior Advisor for chemical, biological, radiological, and nuclear (CBRN) threats and pandemic influenza. In addition to an advisory role, his responsibilities include serving as the FDA point of contact for interagency coordination of policy and program activities in matters related to counterterrorism, emerging threats, and CBRN medical countermeasures.

Prior to rejoining FDA in 2018, Dr. Fisher served as Director, Special Projects and Senior Strategic Information Officer in the Immediate Office of the Assistant Secretary for Preparedness and Response. His prior FDA experience includes review/research experience as a Staff Fellow and Staff Scientist in FDA’s Center for Biologics Research and Review, and as Director of Medical Countermeasure Regulatory Science for FDA’s OCET.

Dr. Fisher received his undergraduate degree in Biology from the University of North Carolina at Pembroke and a Ph.D. in Toxicology from the University of North Carolina at Chapel Hill. He studied filovirus and poxvirus pathogenesis under a National Research Council Research Associateship at the United States Army Medical Research Institute of Infectious Diseases and holds a certificate in Biohazardous Threat Agents and Emerging Infectious Diseases from Georgetown University.


Pre-congress Workshops, April 6 @ 10:00


The role of vaccines in preventing outbreaks, through natural causes or biothreatsIt only takes natural outbreaks and bioterrorism attacks like the Ebola and anthrax to highlight the danger and fragile balance we live in. To ensure global and international security, important decisions need to be made in stockpiling and prioritizing research efforts, however there is a lack of vaccine manufacturers producing these countermeasure treatments. Participate in this workshop to understand the rationale for developers to produce these lower commercial interest vaccines, and the challenges/opportunities associated in working with the government.
  • NIAID’s gap filling preclinical services for vaccine development
  • Expanding the utility of biodefense vaccines
  • Biodefense and Pandemic Preparedness:Two sides of the same coin?
  • Update on the broadly neutralizing influenza monoclonal antibody used for the DARPA-funded Pandemic Preparedness Platform (P3) initiative
  • A disruptive, transportable mRNA vaccine manufacturing platform that can rapidly combat multiple diseases
last published: 05/Mar/20 10:35 GMT

back to speakers

Sign Up for Event Updates